Review of Graft-Versus-Host Disease

Ramachandran, Vignesh; Kolli, Sree S; Strowd, Lindsay C.

doi:10.1016/j.det.2019.05.014

Cited by 106 publications

(103 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of immunosuppressive treatments, and as stem cells are eradicated by chemoradiotherapy, patients are highly immunocompromised and very susceptible to severe infections 23 . Additionally, patients undergoing allogenic HSCT are at risk of graft‐versus‐host disease (GVHD) 24 . GVHD is a major complication after HSCT associated with high morbidity and mortality rates 24 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus

Jolles

Michallet

Agostini³

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

Objectives Secondary antibody deficiency (SAD), associated with severe, recurrent or persistent infections, is common in patients with haematological malignancies (HM), but unifying guidance on immunoglobulin replacement therapy (IgRT) in these patients is lacking. We aimed to develop consensus statements for the use of IgRT in patients with HM. Methods A Delphi exercise was employed to test the level of agreement on statements developed by a Task Force based on available data and their clinical experience. In Round 1, an Expert Panel, comprising specialist EU physicians caring for patients with HM, helped to refine the statements. In Round 2, experts rated their agreement with the statements. In Round 3, experts who had scored their agreement as ≤4 were invited to review their agreement based on the overall feedback. Results Three definitions and 20 statements were formulated and tested for consensus, covering measurement of IgG levels, initiation and discontinuation of IgRT, dosing, and the use of subcutaneous IgG. Consensus (agreement ≥70% on Likert‐type scale) was reached for all three definitions and 18 statements. Conclusions Recommendations have been developed with the aim of providing guidance for the use of IgRT to prevent severe, recurrent or persistent infections in patients with HM and SAD.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Additionally, patients undergoing allogenic HSCT are at risk of graft‐versus‐host disease (GVHD) 24 . GVHD is a major complication after HSCT associated with high morbidity and mortality rates 24 . First‐line treatment of GVHD includes corticosteroids, which further increases the infection risk 23,24 …”

Section: Resultsmentioning

confidence: 99%

Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus

Jolles

Michallet

Agostini³

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…9 a) mucocutaneous eruptions in acute graft vs host disease, and from lichen-planus-like (Fig. 9 b) to scleroderma-like eruptions in chronic graft vs host disease [ 23 , 244 , 245 ]. We believe that extensive discussion of this condition is beyond the scope of the present work, and may be addressed in a separate review.…”

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

“…Finally, it should be considered that the emergence of immune-mediated skin diseases can be the consequence of haematological treatments. Examples are patients undergoing allogenic stem cell transplantation, experiencing 'graft vs host disease' or those treated with immune checkpoint inhibitors, the latter being associated with an increased risk of developing autoimmune bullous skin diseases, such as bullous pemphigoid (BP) [23,24].…”

mentioning

confidence: 99%

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

Haematological malignancies induce important alterations of the immune system, which account for the high frequency of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of haematological malignancies, run a benign clinical course but portend a significant negative impairment on a patient's quality of life. In rare cases, the skin eruption reflects immunological alterations associated with an unfavourable prognosis of the associated haematological disorder. Therapeutic management of immune-mediated skin diseases in patients with haematological malignancies is often challenging. Systemic corticosteroids and immunosuppressive drugs are considered frontline therapies but may considerably augment the risk of serious infections. Indeed, developing a specific targeted therapeutic approach is of crucial importance for this particularly fragile patient population. This review provides an up-to-date overview on the immune-mediated skin diseases most frequently encountered by patients with onco-haematological disorders, discussing new pathogenic advances and therapeutic options on the horizon.

show abstract

“…Histopathologic examination of 2 punch biopsy specimens found a vacuolar interface dermatitis with apoptotic keratinocytes and parakeratosis ( Fig 2 ) consistent with GVHD. 1 This patient had not undergone stem cell transplantation, blood transfusion, or solid organ transplantation. Given the presence of a GVHD-like skin eruption and metastatic thymoma, the diagnosis of thymoma-associated GVHD-like erythroderma was made.…”

Section: Case Reportmentioning

confidence: 99%

Thymoma-associated multiorgan autoimmunity initially manifested by graft-versus-host disease–like erythroderma: Case report and possible therapeutic role of antimalarial drugs

et al. 2020

View full text Add to dashboard Cite

Review of Graft-Versus-Host Disease

Cited by 106 publications

References 112 publications

Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus

Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

Thymoma-associated multiorgan autoimmunity initially manifested by graft-versus-host disease–like erythroderma: Case report and possible therapeutic role of antimalarial drugs

Contact Info

Product

Resources

About